BackArena Pharmaceuticals Overview

Arena Pharmaceuticals Long Term Debt

Track Arena Pharmaceuticals's long-term debt ($36M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$36.16M
12.26% YoYΔ $-5.05M vs prior year quarter

Peer trimmed avg / median

Loading

Arena Pharmaceuticals Long Term Debt History

Loading

Arena Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Arena Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Arena Pharmaceuticals (ARNA) FAQ

As of the most recent data (December 2021), ARNA shows a long-term debt of $36M. That compares with $41M in the prior-year period — down 12.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ARNA's long-term debt is now $36M (was $41M) — a 12.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Arena Pharmaceuticals is outperforming or lagging.

Tracking ARNA's long-term debt over time shows whether Arena Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $36M That compares with $41M in the prior-year period — down 12.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Arena Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $36M) with ownership activity and broader fundamentals.

Arena Pharmaceuticals's long-term debt is $36M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.